<DOC>
	<DOCNO>NCT01706575</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter study evaluate efficacy safety add Pegasys ( peginterferon alfa-2a ) nucleos ( ) ide analogue ( NAs ) treatment participant HBeAg-negative chronic hepatitis B genotype D show stable HBV DNA suppression . After 12-week Lead-in period treatment NA , participant HBsAg decline &lt; 0.5 log10 IU/ml enter Add-on period receive Pegasys 180 mcg subcutaneously weekly 48 week addition current NA treatment . Follow-up 48 week , participant continue NA treatment .</brief_summary>
	<brief_title>A Study Pegasys ( Peginterferon Alfa-2a ) Added Nucleos ( ) Ide Analogue Treatment Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus ( HBV ) Deoxyribonucleic Acid ( DNA ) Suppression</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult participant , 18 65 year age Chronic hepatitis B Negative HBeAg On monotherapy nucleos ( ) ide analogue ( NA ) telbivudine enrolment , HBV DNA persistently 20 IU/ml least 12 month HBsAg &gt; 100 IU/ml begin Leadin phase , confirm addition Pegasys Showing steady HBsAg kinetic ( HBsAg decrease &lt; 0.5 log10 IU/ml Week 12 start Addon phase ) Negative pregnancy test woman childbearing potential Women childbearing potential fertile male female partner childbearing potential must use reliable contraception 3 month Addon phase Coinfection Hepatitis A virus ( HAV ) , Hepatitis C virus ( HCV ) , Hepatitis D virus ( HDV ) , Human Immunodeficiency virus ( HIV ) Evidence decompensated liver disease ( ChildPugh &gt; /=6 ) History evidence medical condition associate chronic liver disease ( e.g . hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure ) Known hypersensitivity peginterferon alfa2a Pregnant breastfeed woman Evidence alcohol and/or drug abuse History severe psychiatric disease , especially depression History immunologically mediate disease History evidence bleed esophageal varix condition consistent decompensated liver disease History evidence severe pulmonary disease associate functional limitation History severe cardiac disease History severe seizure disorder current anticonvulsant use Evidence active suspect cancer history malignancy ( basocellular carcinoma situ cervical carcinoma ) within 5 year prior study entry History receive systemic antineoplastic ( include radiation ) immunomodulatory ( include systemic corticosteroid ) treatment &lt; /= 6 month prior first dose expectation treatment need time study History evidence severe retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>